ERBB2 and gastroesophageal junction adenocarcinoma: Recently, the KEYNOTE-811 trial demonstrated that pembrolizumab can be combined with chemotherapy and trastuzumab in advanced or metastatic HER2-positive GC or GEJ adenocarcinoma, resulting in longer overall survival compared to chemotherapy and trastuzumab alone, which however did not reach the prespecified criteria for significance in the interim analysis.106 Based on the results of these trials, pembrolizumab and nivolumab were approved for the first-line therapy of HER2-negative and CPS-positive cancers in combination with fluoropyrimidine- and platinum-based chemotherapy.